Whether vitamin D3 is effective in reducing proteinuria in type 2 diabetic patients?

Journal of Research in Medical Sciences

Volumn 18, Issue 5, 2013, Pages 374-377

  Ahmadi, Nooshin ^a   Mortazavi, Mojgan ^b   Iraj, Bijan ^c   Askari, Gholamreza ^c  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes; Diabetic nephropathy; Proteinuria; Vitamin D deficiency

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; COLECALCIFEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; VITAMIN D DEFICIENCY;

EID: 84879940789     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Mori H, Okada Y, Tanaka Y. Mutual interaction between vitamin D and lifestyle-related diseases in women. J UOEH 2012;34:323-9.
2. Holick MF, Chen TC. Vitamin D deficiency: A worldwide problem with health consequences. Am J Clin Nutr 2008;87:1080S-6S.
3. Hovsepian S, Amini M, Aminorroaya A, Amini P, Iraj B. Prevalence of vitamin D deficiency among adult population of Isfahan City, Iran. J Health Popul Nutr 2011;29:149-55.
4. Kaykhaei MA, Hashemi M, Narouie B, Shikhzadeh A, Rashidi H, Moulaei N, et al. High prevalence of vitamin D deficiency in Zahedan, southeast Iran. Ann Nutr Metab 2011;58:37-41.
5. John S, Adams W, Hewison M. Update in Vitamin D. Clin Endocrinol Metab 2010;95:471-8.
6. Diaz VA, Mainous AG 3rd, Carek PJ, Wessell AM, Everett CJ. The association of vitamin D deficiency and insufficiency with diabetic nephropathy: Implications for health disparities. J Am Board Fam Med 2009;22:521-7.
7. Agarwal R. Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD. Clin J Am Soc Nephrol 2009;4:1523-8.
8. Tian J, Liu Y, Williams LA, de Zeeuw D. Potential role of active vitamin D in retarding the progression of chronic kidney disease. Nephrol Dial Transplant 2007;22:321-8.
9. Thomas MC, Cooper ME. Into the light? Diabetic nephropathy and vitamin D. Lancet 2010;376:1521-2.
10. Li YC. Vitamin D and diabetic nephropathy. Curr Diab Rep 2008;8:464-9.
11. Hagiwara S, Kantharidis P, Cooper ME. What are new avenues for renal protection, in addition to RAAS inhibition? Curr Hypertens Rep 2012;14:100-10
12. Jódar-Gimeno E, Muñoz-Torres M. Vitamin D hormone system and diabetes mellitus: Lessons from selective activators of vitamin D receptor and diabetes mellitus. Endocrinol Nutr 2013;60:87-95.
13. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxy vitamin D (3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110:229-38.
14. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: A negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004;89-90:387-92.
15. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008;73:163-71.
16. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
17. Bonakdaran S, Hami M, Hatefi A. The effects of calcitriol on albuminuria in patients with type-2 diabetes mellitus. Saudi J Kidney Dis Transpl 2012;23:1215-20.
18. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase. Proc Natl Acad Sci U S A 2008;105:15896-901.
19. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet 2010;376:1543-51.
20. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: A randomized trial. Am J Kidney Dis 2009;54:647-52.
21. Aperis G, Paliouras C, Zervos A, Arvanitis A, Alivanis P. The role of paricalcitol on proteinuria. J Ren Care 2011;37:80-4.
22. Michael F. Holick MF. Vitamin D and health: Evolution, biologic functions, and recommended dietary intakes for vitamin D. Clin Rev Bone Miner Metab 2009;7:2-19.
23. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007;50:69-77.
24. Zehnder D, Quinkler M, Eardley KS, Bland R, Lepenies J, Hughes SV, et al. Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int 2008;74:1343-53.
25. London GM, Guérin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, et al. Mineral metabolism and arterial functions in end-stage renal disease: Potential role of 25-hydroxy vitamin D deficiency. J Am Soc Nephrol 2007;18:613-20.
26. Llach F, Yudd M. Pathogenic, clinical, and therapeutic aspects of secondary hyperparathyroidism in chronic renal failure. Am J Kidney Dis 1998;32:S3-12.